BIIB Quote, Trading Chart, Biogen Inc.
home / stock / biib / biib quote
$333.96 Last:
0.61% Change Percent:
$332.07 Open:
$333.96 Previous Close:
$334.5 High:
$326.5 Low:
928,219 Volume:
07/27/2021 04:41:52 am Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
BIIB Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-07-27 | 332.07 | 333.96 | 334.5 | 326.5 | 928,219 |
| 2021-07-26 | 324.4103 | 331.93 | 335 | 322.51 | 1,265,041 |
| 2021-07-23 | 322.1 | 325.4 | 328.15 | 319.85 | 1,011,273 |
| 2021-07-22 | 320.04 | 326.36 | 330.64 | 319.2282 | 1,485,226 |
| 2021-07-21 | 321.41 | 322.96 | 324.52 | 318.29 | 1,126,418 |
| 2021-07-20 | 324.7 | 322.49 | 327.515 | 317.255 | 1,384,482 |
| 2021-07-19 | 323.08 | 324.16 | 326.97 | 320.11 | 1,032,216 |
| 2021-07-16 | 323.97 | 324.62 | 331.11 | 323 | 1,533,173 |
| 2021-07-15 | 341.85 | 328.16 | 343.04 | 323.71 | 3,007,615 |
| 2021-07-14 | 351.33 | 352.06 | 358.77 | 349.68 | 1,233,331 |
| 2021-07-13 | 349.09 | 351.92 | 357.24 | 347.5 | 973,695 |
| 2021-07-12 | 357.03 | 349.04 | 357.99 | 348.6 | 1,180,761 |
| 2021-07-09 | 371.86 | 358.16 | 372.115 | 351.01 | 2,715,110 |
| 2021-07-08 | 350.07 | 369.05 | 370.0625 | 350.07 | 2,332,688 |
| 2021-07-07 | 344.95 | 355.33 | 355.82 | 344.39 | 1,375,026 |
| 2021-07-06 | 347.6 | 344.89 | 347.71 | 340.27 | 1,039,694 |
| 2021-07-05 | 349.535 | 348.72 | 350.07 | 343.845 | 811,846 |
| 2021-07-02 | 349.535 | 348.72 | 350.07 | 343.845 | 808,720 |
| 2021-07-01 | 346 | 348.92 | 350.38 | 345.46 | 997,728 |
| 2021-06-30 | 345 | 346.27 | 349.5 | 342.75 | 1,062,581 |
News, Short Squeeze, Breakout and More Instantly...
-
Biogen and Ionis report positive topline clinical data on investigational Alzheimer's disease treatment at AAIC - Phase 1b study of BIIB080/IONIS-MAPT Rx met primary objective of safety and tolerability - Study demonstrated durable, robust, time and dose dependent lowering o...
-
Item-level analysis from EMERGE trial shows consistency in slowing decline across cognitive, functional and behavioral measures in early Alzheimer’s disease Presentations include an assessment of the correlation between reductions in amyloid beta and other biomarkers ...
-
Biogen 's (NASDAQ: BIIB) earnings report last week offered us a clear picture of why the biotech company is in need of a change. Its main multiple sclerosis (MS) business is on the decline as blockbuster Tecfidera loses ground to generic competition -- and newer MS drug Vumerity is ...